CSRT.L Regulatory News (CSRT)

This announcement replaces the Consort Medical plc Interim Management Statement released today at 13.07 hours under RNS number 7057Z. The words 'preliminary for the year ended' in the fourth paragraph should read 'interim for the six months ended' and not as previously stated. All other details remain unchanged. The full announcement text is repeated below.

News Release

20 March 2012

Consort Medical plc

Interim Management Statement

Consort Medical plc (LSE: CSRT), today issues its Interim Management Statement for the period from 1 November to date.

Bespak has continued to trade strongly with encouraging valve and device shipments. Launch stocks are already being manufactured for three of the customer programmes scheduled for launch in 2012 and good progress has been made across the development portfolio. In particular, we are pleased that prototype Point Of Care (POC) diagnostic cartridges have been shipped to Atlas Genetics for evaluation, and that product was supplied on schedule to Kind Consumer for clinical trials.

Underlying demand for King Systems' core products in the US has continued to be consistent with the prior year. We have experienced good growth in sales of airway management products, especially the King Laryngeal Tube range. The King Vision video laryngoscope continues to grow revenues in line with expectations, with particular traction in the Emergency Medical Service (EMS) setting. In response to the potential size of the EMS opportunity, we have been pleased to enter into a non-exclusive distribution agreement with Bound Tree, a leading distributor of medical devices in the EMS segment, to expand our market access in this important segment.

There has been no significant change in the Group's financial position since the publication of the Group's interim results for the six months ended 31 October 2011 in December 2011. The Group remains strongly cash generative.

The Board remains confident about the outlook for the full year.

For enquiries, please contact:

Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.

Consort Medical develops and manufactures metered dose inhaler valves, actuators, compliance aids, dry powder devices autoinjectors, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in King's Lynn, Sheffield, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).